Immunotec wins two gold Globee Awards for growth and Immunocal innovation

Immunotec earned two Gold Globee Awards in the 2026 Globee Awards for Business, including Best of Category honors for rapid growth and for its flagship Immunocal product. The wins spotlight the company’s expansion to 31 markets and nearly three decades of research behind Immunocal.

Why it matters: - The awards signal that Immunotec is being recognized not just for sales growth, but for pairing growth with profitability and sustained scientific investment. - The recognition also reinforces Immunocal’s role as the company’s core product and research engine after about 30 years in market. - Immunotec now has a higher-profile platform to support expansion across its global business and independent consultant network.

What happened: - Immunotec won two Gold Globee® Awards in the 16th Annual 2026 Globee® Awards for Business. - Both wins also received Best of Category honors. - The company was recognized in Achievement in Rapid Growth & Scaling and HealthTech, Life Sciences or Biotech Product or Service of the Year. - Mauricio Domenzain, chief executive officer of Immunotec, said the awards reflect the company’s growth and continued commitment to the science behind Immunocal.

The details: - The Rapid Growth & Scaling award recognized Immunotec’s expansion while the company strengthened profitability and its existing business. - Immunotec said annual revenue rose from about $145 million in 2023 to $200 million in 2025. - EBITDA increased from about $10 million to nearly $25 million over the same period. - The company said the results reflect sustainable expansion, operational efficiency and long-term financial strength. - Immunotec operates in 31 markets across North America, Latin America and Europe, with a recent expansion into Asia. - The company says its growth is supported by a growing international community of customers and independent consultants. - The Immunocal award recognized the product for three decades of innovation and contributions to life sciences research. - Immunocal has been supported by more than 90 scientific publications and 26 blinded human clinical trials. - Immunotec says it has continued to expand its intellectual property portfolio through research and patented innovations involving Immunocal and related applications. - Immunotec says it delivered more than 10 million boxes of Immunocal to customers worldwide over the past five years.

Between the lines: - The twin awards suggest Immunotec wants to be seen as both a growth company and a science-driven health business. - The recognition helps position financial performance and product credibility as mutually reinforcing strengths. - The emphasis on profitability, not just expansion, points to a more disciplined growth narrative.

What's next: - Immunotec says it will keep expanding internationally while strengthening operations. - The company also plans to keep investing in research tied to its product portfolio. - Continued growth in established markets and newer regions such as Asia appears to be part of the next phase.

The bottom line: - Immunotec used the Globee® stage to showcase a rare combination of market expansion, improved profitability and long-running product science. - For more information, visit Immunotec’s website.